Inhibition of IGF2BP1 was shown to sensitize a variety of cancer cells to therapeutics [57,58,59], and it was demonstrated to be especially effective in reducing the resistance of chemotherapy-resistant CRC cells with activated Wnt/β-catenin signaling [60]. The gene discussed is IGF2BP1; the disease is cancer.